E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/2/2018 in the Prospect News Structured Products Daily.

New Issue: RBC prices $922,000 contingent coupon barrier autocallables tied to two stocks

By Devika Patel

Knoxville, Tenn., Feb. 2 – Royal Bank of Canada priced $922,000 of autocallable contingent coupon barrier notes due Jan. 29, 2021 linked to the stocks of Celgene Corp. and GlaxoSmithKline plc, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will pay a contingent quarterly coupon at an annual rate of 9.3% if each stock closes at or above the 70% coupon barrier level on the observation date for that quarter.

The notes will be called at par plus the coupon if each stock closes at or above its initial price on any quarterly observation date beginning July 26, 2018.

The payout at maturity will be par plus the coupon unless either stock finishes below the 70% trigger level, in which case investors will lose 1% for each 1% decline of the worst performing stock from its initial level.

RBC Capital Markets, LLC is the underwriter.

Issuer:Royal Bank of Canada
Issue:Autocallable contingent coupon barrier notes
Underlying stocks:Celgene Corp. (Symbol: CELG) and GlaxoSmithKline plc (Symbol: GSK)
Amount:$922,000
Maturity:Jan. 29, 2021
Coupon:9.3%, payable quarterly if each stock closes at or above coupon barrier level on observation date for that quarter
Price:Par
Payout at maturity:Par plus the coupon unless either stock finishes below trigger level, in which case 1% loss for each 1% decline of worst performing stock from initial level
Call:At par plus coupon if each stock closes at or above initial price on any quarterly observation date beginning July 26, 2018
Initial levels:$105.17 for Celgene and $39.04 for GlaxoSmithKline
Coupon barrier/Trigger levels:$73.62 for Celgene and $27.33 for GlaxoSmithKline, 70% of initial levels
Pricing date:Jan. 26
Settlement date:Jan. 31
Agents:RBC Capital Markets, LLC
Fees:2.25%
Cusip:78013XEH7

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.